Is there benefit in implanting defibrillators in patients with severe heart failure?

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Current practice often excludes patients with severe heart failure from receiving implantable cardioverter defibrillators (ICDs).
• This exclusion is based on the assumption that their deaths are non-sudden and thus not preventable by ICDs.
• This assumption suggests that the benefits of ICDs should decrease in subgroups with more severe heart failure.

Purpose of the Study:

• To investigate whether patients with severe heart failure benefit less from implantable cardioverter defibrillators (ICDs).
• To challenge the prevailing assumption that severe heart failure limits the effectiveness of ICD therapy.

Main Methods:

• Analysis of data from six randomized controlled trials involving 7873 patients, with 2734 assigned to ICDs.
• Subgroup analysis based on New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF).
• Evaluation of mortality reduction and z-scores across different severity subgroups.

Main Results:

• No significant difference in z-scores was observed between mild-to-moderate and severe heart failure patients when categorized by NYHA class (p=0.922).
• Subgrouping by LVEF also showed no significant difference in z-scores (p=0.170).
• These findings indicate that the benefit of ICD implantation is not attenuated in patients with higher NYHA class or lower LVEF.

Conclusions:

• Existing trial data do not support the notion that the relative risk reduction from ICDs is smaller in patients with severe heart failure.
• The assumption that severe heart failure patients benefit less from ICD therapy requires re-evaluation.
• Further consideration of ICD implantation in severe heart failure populations is warranted.